GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (NAS:SILK) » Definitions » Additional Paid-In Capital

Silk Road Medical (Silk Road Medical) Additional Paid-In Capital : $560.9 Mil(As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical Additional Paid-In Capital?


Silk Road Medical's quarterly additional paid-in capital increased from Sep. 2023 ($539.8 Mil) to Dec. 2023 ($550.5 Mil) and increased from Dec. 2023 ($550.5 Mil) to Mar. 2024 ($560.9 Mil).

Silk Road Medical's annual additional paid-in capital increased from Dec. 2021 ($367.9 Mil) to Dec. 2022 ($507.7 Mil) and increased from Dec. 2022 ($507.7 Mil) to Dec. 2023 ($550.5 Mil).

Silk Road Medical Additional Paid-In Capital Historical Data

The historical data trend for Silk Road Medical's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silk Road Medical Additional Paid-In Capital Chart

Silk Road Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 263.38 346.32 367.91 507.72 550.50

Silk Road Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 517.66 529.45 539.83 550.50 560.85

Silk Road Medical Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Silk Road Medical Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Silk Road Medical (Silk Road Medical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (NAS:SILK) » Definitions » Additional Paid-In Capital
Comparable Companies
NNOX CVRX LUNG TCMD SENS ARAY RCEL CERS BVS ALUR ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
2OW:Germany
Address
1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089
Website
https://www.silkroadmed.com
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Executives
Chas Mckhann director, officer: Chief Executive Officer 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Marie L. Jones officer: CAO and VP, Finance 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Lucas W. Buchanan officer: Chief Financial Officer C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Kevin M Klemz officer: EVP/Chief Legal Officer/Sec. 9600 54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55442
Andrew S. Davis officer: Chief Commercial Officer C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Erica J. Rogers director, officer: President and CEO C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard Ruedy officer: EVP Clin & Reg. Affairs and QA C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tony M. Chou director C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tanisha Carino director C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Kevin J. Ballinger director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Rick D Anderson director 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Donald Zurbay director C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Warburg Pincus Partners Gp Llc 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus & Co. 10 percent owner 450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147